Akero Therapeutics Inc., a clinical-stage company based in South San Francisco, California, is dedicated to developing innovative treatments for patients with serious metabolic diseases that have limited treatment options. The company announced that management will be presenting at the BofA Securities 2024 Health Care Conference on May 14th, 2024, in Las Vegas, NV. The presentation will take place at 5:00 p.m. P.T. and will be available for viewing via a live webcast on the company’s investor relations section of their website, www.akerotx.com. After the live webcast, an archived replay will also be accessible on the website.
Akero Therapeutics is focused on addressing the high unmet medical needs of patients with metabolic diseases, including MASH. Their lead product candidate, EFX, is currently undergoing evaluation in a 96-week Phase 2b clinical trial called the SYMMETRY study. This trial involves patients with compensated cirrhosis due to MASH (F4 fibrosis). Additionally, the company has two ongoing Phase 3 clinical trials: the SYNCHRONY Histology study in patients with pre-cirrhotic MASH (F2-F3 fibrosis) and the SYNCHRONY Real-World study in patients with MASH (F1-F3 fibrosis) or MASLD.
A third clinical trial, known as the SYNCHRONY Outcomes study, is set to begin in the second quarter of 2024. This study will focus on patients with compensated cirrhosis due to MASH (F4 fibrosis). The Phase 3 SYNCHRONY program is based on the positive results of two Phase 2b trials: the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero Therapeutics is headquartered in South San Francisco and more information can be found on their website at akerotx.com. For additional updates, follow the company on LinkedIn and Twitter.
For investor inquiries, please contact Christina Tartaglia at Stern Investor Relations, Inc. at 212.362.1200 or christina.tartaglia@sternir.com. Media inquiries can be directed to Sarah O’Connell at 732.456.0092 or soconnell@vergescientific.com.